Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Vitamin A keeps the GVHD away?

Zachariah DeFilipp

Blood (2024) 143 (12): 1067.

https://doi.org/10.1182/blood.2024023828

Published: 2024

Journal Articles

Spatial transcriptomics reveals distinct tissue niches linked with steroid responsiveness in acute gastrointestinal GVHD

Bidish K. Patel, Michael J. Raabe, Evan R. Lang, Yuhui Song, Chenyue Lu, Vikram Deshpande, Linda T. Nieman, Martin J. Aryee, Yi-Bin Chen, David T. Ting, Zachariah DeFilipp

Blood (2023) 142 (21): 1831–1844.

https://doi.org/10.1182/blood.2023020644

Published: 2023

Includes: Supplemental data

Journal Articles

Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis

Gabriela S. Hobbs, Haesook T. Kim, Suzanne O'Connor, Mark A. Schroeder, Roni Tamari, Sarah A Wall, Areej El-Jawahri, Steven McAfee, Jessica Hem, Patricia Lozano, Jonas S. Jutzi, Ann Mullally, Yi-Bin Chen, Zachariah Defilipp

Blood (2023) 142 (Supplement 1): 2103.

https://doi.org/10.1182/blood-2023-178645

Published: 2023

Journal Articles

A Day 14 Endpoint for Acute Gvhd Clinical Trials

Blood (2023) 142 (Supplement 1): 779.

https://doi.org/10.1182/blood-2023-172955

Published: 2023

Journal Articles

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah Defilipp, David I Lichter, Jonathan U Peled, Marcel R.M. van den Brink, Kelly Brady, Matthew D Puhl, Gabrielle Glick, Brooke Hasson, Barbara H McGovern, Lisa von Moltke, Bina Tejura

Blood (2023) 142 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2023-180119

Published: 2023

Journal Articles

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Blood (2023) 142 (Supplement 1): 1.

https://doi.org/10.1182/blood-2023-186963

Published: 2023

Journal Articles

A Phase II Multicenter Trial of Ruxolitinib to Treat Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation

Zachariah Defilipp, Haesook T. Kim, Guang-Shing Cheng, Saurabh Chhabra, Mehdi Hamadani, Karamjeet S. Sandhu, Betty K. Hamilton, Lia Perez, Catherine J. Lee, Timothy L Brennan, Cassandra Garrelts, Bergin M Brown, Kathleen Gallagher, Areej El-Jawahri, Yi-Bin Chen

Blood (2023) 142 (Supplement 1): 775.

https://doi.org/10.1182/blood-2023-179365

Published: 2023

Journal Articles

Multi-Site Randomized Trial of Inpatient Palliative Care for Hospitalized Patients Undergoing Hematopoietic Stem Cell Transplantation

Areej El-Jawahri, Thomas W LeBlanc, Alison Kavanaugh, Jason Webb, James Fausto, Lara Traeger, Joseph Greer, Vicki Jackson, Nora Horick, Zachariah Defilipp, Yi-Bin Chen, Stephanie J. Lee, Jennifer Temel

Blood (2023) 142 (Supplement 1): 913.

https://doi.org/10.1182/blood-2023-185735

Published: 2023

Journal Articles

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Jonathan U. Peled, Marcel R.M. van den Brink, Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah DeFilipp, Bina Tejura, David I Lichter, Mary-Jane Lombardo, Meghan Chafee, Jennifer R Wortman, Timothy Straub, Emily Walsh, Augustus Ge, David Lyttle, Brooke Hasson, Christopher Ford, Lisa von Moltke, Matthew Henn

Blood (2023) 142 (Supplement 1): 2198.

https://doi.org/10.1182/blood-2023-188885

Published: 2023

Journal Articles

Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial

Blood (2023) 142 (Supplement 1): 649.

https://doi.org/10.1182/blood-2023-180142

Published: 2023

Journal Articles

Multimodal Mobile Application to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant (HCT) Survivors

Areej El-Jawahri, Jennifer Reese, Lara Traeger, Don Dizon, Sharon Bober, Julie Vanderklish, Richard Newcomb, Zachariah Defilipp, Yi-Bin Chen, Jennifer Temel

Blood (2023) 142 (Supplement 1): 5142.

https://doi.org/10.1182/blood-2023-185776

Published: 2023

Journal Articles

Maintenance Ruxolitinib Is Associated with Low Rates of Chronic Gvhd Requiring Systemic Treatment in Older Adults with AML/MDS Undergoing Allogeneic HCT: Results of a Phase II Multicenter Trial

Zachariah Defilipp, Haesook T. Kim, Laura Knight, Suzanne O'Connor, Meghan White, Bhagirathbhai Dholaria, Mark A. Schroeder, Sumithira Vasu, Sameem Abedin, Areej El-Jawahri, Steven McAfee, Yi-Bin Chen, Gabriela S. Hobbs

Blood (2023) 142 (Supplement 1): 653.

https://doi.org/10.1182/blood-2023-180423

Published: 2023

Journal Articles

The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd

Blood (2023) 142 (Supplement 1): 3576.

https://doi.org/10.1182/blood-2023-182300

Published: 2023

Journal Articles

Prediction of Graft-Versus-Host Disease (GVHD) in Recipients of Hematopoietic Cell Transplant(alloHCT) from a Single Mismatched Unrelated Donor Using a Highly Multiplexed Proteomics Assay: MHC-Pepseq

Karamjeet S. Sandhu, John Altin, Tao Wang, Jakob Devos, Medhat Askar, Zachariah DeFilipp, Ketevan Gendzekhadze, Carrie L. Kitko, Stephanie J. Lee, Margaret L. MacMillan, Stephen R. Spellman, Ryotaro Nakamura

Blood (2023) 142 (Supplement 1): 4930.

https://doi.org/10.1182/blood-2023-186724

Published: 2023

Journal Articles

A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma

Blood (2023) 142 (7): 621–628.

https://doi.org/10.1182/blood.2023020244

Published: 2023

Journal Articles

Effective treatment of low-risk acute GVHD with itacitinib monotherapy

Blood (2023) 141 (5): 481–489.

https://doi.org/10.1182/blood.2022017442

Published: 2023

Includes: Supplemental data

Journal Articles

How I treat with maintenance therapy after allogeneic HCT

Zachariah DeFilipp, Yi-Bin Chen

Blood (2023) 141 (1): 39–48.

https://doi.org/10.1182/blood.2021012412

Published: 2023

Journal Articles

RGI-2001 Infusion for Prevention of Acute Gvhd after Allogeneic Hematopoietic Cell Transplantation

Yi-Bin Chen, Ayman Saad, Shatha Y. Farhan, Lazaros J. Lekakis, Gary J. Schiller, Jean A. Yared, Amer Assal, Dana D Lee, Hayley Lane, Ted A. Gooley, Zachariah Defilipp

Blood (2022) 140 (Supplement 1): 1877–1878.

https://doi.org/10.1182/blood-2022-162512

Published: 2022

Journal Articles

Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy

Blood (2022) 140 (Supplement 1): 1867–1869.

https://doi.org/10.1182/blood-2022-156000

Published: 2022

Journal Articles

Spatial Transcriptomics of Tissue-Based Immune Response to Acute Graft-Versus-Host Disease of the Lower Gastrointestinal Tract

Bidesh Kumar Patel, Michael J Raabe, Vikram Deshpande, David T Ting, Yi-Bin Chen, Zachariah Defilipp

Blood (2022) 140 (Supplement 1): 1385–1386.

https://doi.org/10.1182/blood-2022-162847

Published: 2022

NARROW

Vitamin A keeps the GVHD away?

Spatial transcriptomics reveals distinct tissue niches linked with steroid responsiveness in acute gastrointestinal GVHD

Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis

A Day 14 Endpoint for Acute Gvhd Clinical Trials

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

A Phase II Multicenter Trial of Ruxolitinib to Treat Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation

Multi-Site Randomized Trial of Inpatient Palliative Care for Hospitalized Patients Undergoing Hematopoietic Stem Cell Transplantation

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial

Multimodal Mobile Application to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant (HCT) Survivors

Maintenance Ruxolitinib Is Associated with Low Rates of Chronic Gvhd Requiring Systemic Treatment in Older Adults with AML/MDS Undergoing Allogeneic HCT: Results of a Phase II Multicenter Trial

The MAGIC Algorithm Probability Predicts Long-Term Outcomes and Treatment Response to Second-Line Therapy for Acute Gvhd

Prediction of Graft-Versus-Host Disease (GVHD) in Recipients of Hematopoietic Cell Transplant(alloHCT) from a Single Mismatched Unrelated Donor Using a Highly Multiplexed Proteomics Assay: MHC-Pepseq

A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma

Effective treatment of low-risk acute GVHD with itacitinib monotherapy

How I treat with maintenance therapy after allogeneic HCT

RGI-2001 Infusion for Prevention of Acute Gvhd after Allogeneic Hematopoietic Cell Transplantation

Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy

Spatial Transcriptomics of Tissue-Based Immune Response to Acute Graft-Versus-Host Disease of the Lower Gastrointestinal Tract

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only